Source Pravda.Ru

India’s Ranbaxy won approval to make and sell the anti-diabetes drug in U.S.

Indian pharmaceutical giant Ranbaxy said Friday it had received final approval from the U.S. Food and Drug Administration to make and sell the anti-diabetes drug glimipiride in the United States.

Glimepiride is the generic equivalent of Sanofi Aventis SA's anti-diabetic agent Amaryl, whose patent just expired. The brand has annual sales of about $350 million (Ђ287 million). Officials at the FDA and Aventis could not be immediately reached for comment.

Ranbaxy said in a statement that it had received approval to sell the tablets in doses of 1 milligram, 2 milligrams, 3 milligrams, 4 milligrams, 6 milligrams and 8 milligrams, reports the AP. I.L.

In response to the unlawful December 1 arrest and detention of Chinese tech giant Huawei's chief financial officer Sabrina Meng Wanzhou by Canadian authorities in Vancouver at the behest of the Trump regime, facing possible unacceptable extradition to the US, Beijing warned its high-tech personnel last month against traveling to America unless it's essential.

China Warns Against Travel to US and Canada